比克替拉韦/恩曲他滨/丙酚替诺福韦与基于多替拉韦的三药方案在不同依从性HIV感染者中的疗效比较
基于五项3期双盲安慰剂对照研究,回顾性分析2622例HIV感染者依从性与病毒学结局。第48周时B/F/TAF组低依从者(3.5%)病毒学抑制与高/中依从者相似,而DTG+2NRTIs组低依从者(5.2%)抑制率较低(P≤0.002);第96和144周结果相似。
要点
- 低依从(<85%)者中,B/F/TAF组病毒学抑制与高/中依从者相似。
- DTG+2NRTIs组低依从者病毒学抑制低于高/中依从者(P≤0.002)。
- DTG+2NRTIs组2例<95%依从者出现M184V,B/F/TAF组无治疗 emergent 耐药。
核心结论
- 依从性欠佳(<85%)时,B/F/TAF组仍维持高水平病毒学抑制,而DTG+2NRTIs组依从性欠佳与较低病毒学抑制相关。
研究设计与样本
- 五项3期双盲安慰剂对照研究(NCT02607930、NCT02607956、NCT03547908、NCT02603120、NCT03110380)的回顾性分析,纳入初治或病毒学抑制的成人。
- 共2622例参与者,B/F/TAF组n=1306,DTG+2NRTIs组n=1316。
- 依从性按回收药瓶计数计算,病毒学结局采用末次治疗中HIV-1 RNA评估。
主要发现
- 截至第48周,B/F/TAF组低依从者46例(3.5%,中位依从性78%),DTG+2NRTIs组69例(5.2%,中位依从性80%)。
- 截至第48周,B/F/TAF组1287例(98.5%)和DTG+2NRTIs组1292例(98.2%)达到病毒学抑制(HIV-1 RNA<50拷贝/mL)。
- 低依从者病毒学抑制与高/中依从者比较:B/F/TAF组相似,DTG+2NRTIs组较低(P≤0.002)。
- 第96周和第144周观察到相似结果。
- DTG+2NRTIs组2例<95%依从者(接受DTG和阿巴卡韦/拉米夫定)出现M184V,B/F/TAF组无治疗 emergent 耐药。
关键数值与推荐
- 依从性分类:高(≥95%)、中(≥85%至<95%)、低(<85%)。
- 病毒学抑制定义为HIV-1 RNA<50拷贝/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Five Phase 3 bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) clinical studies demonstrated that the efficacy of B/F/TAF was non-inferior to dolutegravir (DTG) + 2 NRTIs. We retrospectively assessed drug adherence and effect on virologic outcomes. METHODS: Studies (NCT02607930, NCT02607956, NCT03547908, NCT02603120 and NCT03110380) were double-blind, placebo-controlled and enrolled treatment-naïve or virologically suppressed adults. Adherence was calculated by pill count from returned pill bottles; virologic outcome was assessed by last on-treatment HIV-1 RNA. RESULTS: Altogether, 2622 participants (B/F/TAF: n = 1306; DTG + 2 NRTIs: n = 1316) were categorized as having high (≥95%), intermediate (≥85% to <95%) or low (<85%) adherence. Through Week 48, low adherence was observed in 46 (3.5%) participants in the B/F/TAF group (78% median adherence) and 69 (5.2%) in the DTG + 2 NRTI group (80% median adherence). Overall, 1287 (98.5%) participants in the B/F/TAF group and 1292 (98.2%) in the DTG + 2 NRTI group had virologic suppression (VS; HIV-1 RNA < 50 copies/mL) through Week 48. VS in participants with low adherence versus high or intermediate adherence was similar in the B/F/TAF group, but lower in the DTG + 2 NRTI group (P ≤ 0.002). Similar results were observed at Weeks 96 and 144. Two participants (<95% adherence) in the DTG + 2 NRTI group receiving DTG and abacavir/lamivudine developed M184V; there was no treatment-emergent resistance to B/F/TAF. CONCLUSIONS: Participants with suboptimal (<85%) adherence to B/F/TAF maintained high levels of VS, whereas suboptimal DTG + 2 NRTI adherence was associated with lower VS.
引用
- Andreatta K, Sax PE, Wohl D, et al. Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy. J Antimicrob Chemother. 2025. PMID: 39556192. doi:10.1093/jac/dkae407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。